Some patients may require adjuvant endocrine therapy (aromatase inhibitor by suppressing plasma estrogen levels or selective estrogen receptor modulator by competitive antagonism of the estrogen receptor) for the woman with hormonal receptor-positive BC for a period of five to 10 years. This evidence concerns the gene ESR1 and breast cancer.